Expertise in
8
conditions

Dr. Katarzyna Jamieson

Hematology
UNC Hospitals Pulmonary Function Lab
101 Manning Dr, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
UNC Hospitals Pulmonary Function Lab
101 Manning Dr, 
Chapel Hill, NC 

Overview

Katarzyna Jamieson is a Hematologist in Chapel Hill, North Carolina. Dr. Jamieson is highly rated in 8 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in FL

Hospital Affiliations

Unc Hospitals

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UNC Hospitals Pulmonary Function Lab
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma
Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Biological, Drug
Study Drugs: ATLCAR.CD30 T cells, Bendamustine, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological
Study Drug: ATLCAR.CD30 cells
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: August 06, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Drug
Study Drug: Anti-CD30 CAR-T Cells
Study Phase: Phase 1
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
View 5 Less Clinical Trials

21 Total Publications

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 30, 2025
Similar Doctors
Expertise in
40
conditions
Dr. Tapan Kadia
Hematology
Expertise in
40
conditions
Dr. Tapan Kadia
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (19.7 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist in Cary, North Carolina. Dr. Kadia is highly rated in 40 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Prolymphocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
32
conditions
Dr. Nigel Key
Hematology | Oncology
Expertise in
32
conditions
Dr. Nigel Key
Hematology | Oncology

UNC Hospitals Outpatient Center At Eastowne

100 Eastowne Dr, 
Chapel Hill, NC 
 (4.0 miles away)
984-974-2695
Languages Spoken:
English
See accepted insurances

Nigel Key is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Key is highly rated in 32 conditions, according to our data. His top areas of expertise are Hemophilia B, Hemophilia A, Blood Clots, and Sickle Cell Disease.

Expertise in
33
conditions
Dr. Prithviraj Bose
Hematology
Expertise in
33
conditions
Dr. Prithviraj Bose
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (19.7 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prithviraj Bose is a Hematologist in Cary, North Carolina. Dr. Bose is highly rated in 33 conditions, according to our data. His top areas of expertise are Myelofibrosis, Essential Thrombocythemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Katarzyna Jamieson

How do I make an appointment with Dr. Katarzyna Jamieson?

You can book an appointment with Dr. Katarzyna Jamieson by calling their office at 919-966-2538. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Katarzyna Jamieson a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Katarzyna Jamieson is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Katarzyna Jamieson specialize in?

While Dr. Katarzyna Jamieson is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Acute Myeloblastic Leukemia without Maturation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Katarzyna Jamieson participate in research or clinical trials?

Yes. Dr. Katarzyna Jamieson has published 21 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Katarzyna Jamieson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Katarzyna Jamieson accept my insurance?

Dr. Katarzyna Jamieson accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 919-966-2538 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jamieson's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile